CN107298719A - Pre-dyed luminescent protein marker preparation method - Google Patents

Pre-dyed luminescent protein marker preparation method Download PDF

Info

Publication number
CN107298719A
CN107298719A CN201710707539.4A CN201710707539A CN107298719A CN 107298719 A CN107298719 A CN 107298719A CN 201710707539 A CN201710707539 A CN 201710707539A CN 107298719 A CN107298719 A CN 107298719A
Authority
CN
China
Prior art keywords
dyed
luminescent protein
albumen
genes
marker
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201710707539.4A
Other languages
Chinese (zh)
Inventor
方卫斌
张海灵
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tian Yue (beijing) Biotechnology LLC
Original Assignee
Tian Yue (beijing) Biotechnology LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tian Yue (beijing) Biotechnology LLC filed Critical Tian Yue (beijing) Biotechnology LLC
Priority to CN201710707539.4A priority Critical patent/CN107298719A/en
Publication of CN107298719A publication Critical patent/CN107298719A/en
Pending legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4722G-proteins
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70Vectors or expression systems specially adapted for E. coli
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/30Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Abstract

The invention provides a kind of pre-dyed luminescent protein marker preparation method, its step includes:The weight chain constant area gene (CH genes) of proteinA genes, proteinG genes, MBP gene, mouse and rabbit source antibody is obtained, said gene is cut or combined according to each albumen size in pre-dyed luminescent protein marker;Expressing protein, purifying, the albumen of different molecular weight is mixed according to a certain percentage, luminescent protein marker is obtained;The luminescent protein marker mixed up and pre-dyed albumen marker is mixed in different ratios.The pre-dyed luminescent protein marker of the present invention can recognize the primary antibody or secondary antibody of separate sources, add the binding site of albumen, strengthen optical signal, can not only in electrophoresis process and transferring film after indicator protein approximate location, and can on X films indicator protein exact position, without extra increase pre-dyed marker swimming lanes, and extra antibody need not be added, luminescent protein can combining source in the IgG or anti-rabbit and the secondary antibody of mouse of the species such as people, rat, mouse, rabbit.

Description

Pre-dyed luminescent protein marker preparation method
Technical field
The present invention relates to a kind of pre-dyed luminescent protein marker preparation method, belong to molecular biology and led with genetic engineering Domain.
Background technology
Protein marker is widely used in protein electrophorese as a kind of standard of protein molecular weight size.It The mixture being made up of the albumen or polypeptide of known different molecular weight size.Western Blot need one kind to be used for tracking The scale of the positive antigen signals of detection and transferring film efficiency, then generates pre-dyed albumen Marker.Pre-dyed albumen Marker be by Each albumen (or polypeptide) in general proteins marker passes through chemical modification, and the dyestuff with a kind of blueness or other colors is covalent Coupling is formed.Pre-dyed albumen marker appearance brings great convenience to Western Blot, and researcher, can root after transferring film The Position Approximate of purpose band is determined according to film blue (or other colors) albumen marker size, so as to be cut to film The processing such as cut.But, pre-dyed albumen Marker can not be exposed on film, and exposure signal is needed according to the pre-dyed albumen on film Marker judges that in addition mobility changes pre-dyed albumen Marker in SDS-PAGE electrophoresis processes after chemical modification Become, molecular weight information is no longer accurate, often lead to Western Blot results and judge relatively large deviation occur.
Luminous Western Blot Marker are the molecular weight standards exclusively for Western Blot experimental designs. In western blot experiments, marker bands can specifically bind primary antibody or secondary antibody, make protein sample and albumen marker After chemiluminescence detection, it can be shown simultaneously on X-ray.
It can be used for the luminous marker of exposure on the market at present, different company employs different technologies.CST companies Luminous marker be purifying albumen and the covalently bound mixture of biotin, antibiotin HRP antibody is in Western It is used for detecting biotinylated protein ladder in blots.Most of companies are luminous using the albumen composition for being capable of binding antibody IgG Marker composition, such as thermo.
But, all there is certain deficiency in current product, biotinylated albumen marker need to add antibiotin- HRP antibody or streptavidin-HRP, this causes experimental implementation to become cumbersome.In addition, only containing the albumen that can be lighted Marker be unable to the positive antigen signals of tracing detection with transferring film efficiency, it is necessary in addition plus together with pre-dyed marker, it is not only cumbersome and And take swimming lane, reduce can electrophoresis sample size.
The content of the invention
The present invention is intended to provide one kind can be shown with destination protein on X films, so as to more accurately indicate simultaneously The particular location of albumen, and the pre-dyed luminescent protein marker of additional agents preparation method need not be added.
The purpose of the present invention is achieved through the following technical solutions:
A kind of pre-dyed luminescent protein marker preparation method, its step includes:
A, the heavy chain constant region base for obtaining proteinA genes, proteinG genes, MBP genes, mouse and rabbit source antibody Because of (CH genes), the IgG Binding domain for determining proteinA, proteinG are annotated according to NCBI, it is luminous according to pre-dyed Each albumen size is cut or group to proteinA genes, proteinG genes, MBP genes, CH genes in albumen marker Close, the Binding domain of albumen are retained in cutting process;
B, proteinA, proteinG, MBP and CH gene after cutting or combination is connected on expression vector respectively Carry out expression and purification, the albumen purified;
C, the albumen of different molecular weight mixed according to a certain percentage, obtain luminescent protein marker;
D, the luminescent protein marker mixed up and pre-dyed albumen marker mixed in different ratio, by observing transferring film Stripe depth and band brightness selection proper mixture ratio example on X films after development on caudacoria.
It is preferred that, the expression vector is pET21a or pET28a.
It is preferred that, the host cell is E.coli.
It is preferred that, the luminescent protein marker molecular weight is from 16kDa to 200kDa.
The pre-dyed luminescent protein marker of the present invention is in mutually not shadow by luminescent protein marker and pre-dyed albumen marker Mixed according to a certain percentage in the case of sound, so as to realize the molecule figureofmerit after transferring film and molecule on X films after exposure Figureofmerit dual-use function, wherein luminescent protein marker be proteinA, proteinG by being capable of binding antibody IgG or ProteinL, and can be formed by the rabbit source of two anti-bindings or mouse source antibody Fc district gene fusion expression, so that luminescent protein Albumen in marker can recognize the primary antibody or secondary antibody of separate sources, add the binding site of albumen, strengthen optical signal. The present invention pre-dyed luminescent protein marker can not only in electrophoresis process and transferring film after indicator protein approximate location, Er Qieneng The exact position of indicator protein on X films, without extra increase pre-dyed marker swimming lanes, and need not be added extra Antibody, such as anti-biotin antibodies-HRP or streptavidin-HRP, luminescent protein can combining source in people, rat, mouse, rabbit etc. The IgG or anti-rabbit and the secondary antibody of mouse of species.Compared with the luminous marker of other companies, with broader indicating range, point Son amount is from 16kDa to 200kDa.
Brief description of the drawings
Fig. 1 for can luminescent protein marker exposure after electrophoretogram.
Fig. 2 is the electrophoretogram before pre-dyed luminescent protein marker exposes.
Fig. 3 is the electrophoretogram after pre-dyed luminescent protein marker exposes.
Fig. 4 is the architectural feature figure of the polyclonal sequences of MBP+.
The present invention is further described in detail with reference to embodiment, the embodiment provided is only for explaining The bright present invention, and be not construed as limiting the scope of the present invention.
Embodiment
Embodiment one
1st, synthesis staphylococcus aureus immunity Lysozyme associated proteins A (proteinA) and streptococcus immune globulin G Associated proteins G (proteinG) complete genome sequence;Buy plasmid pFUSEss-CHIg-rG*03 (InvivoGen, Catalog# Pfusess-rchg) resist with pFUSEss-CHIg-mG2b (InvivoGen, Catalog#pfusess-mchg2b) as rabbit source Weight chain constant area gene (mFc) pcr template of body weight chain constant area gene (rFc) and mouse source antibody;From the pET28a- of structure His-MBP carriers are MBP sequence pcr templates.
2nd, pET28a-his-MBP vector constructions
According to pMal-C2T (GenBank:JF795283.1 the MBP nucleotide sequences design polyclonal sequences of his+MBP+ in) (SEQ ID NO.9), is synthesized by Sangon Biotech (Shanghai) Co., Ltd. and is built into many grams of pET28a-his-MBP Grand carrier.
3rd, different genetic fragment combinations are designed according to each band molecular size range in luminous marker, specific combination is shown in Table 1:
The luminescent protein marker bands of table 1 are constituted
Note:pA:proteinA
pG:proteinG
According to each genetic fragment design primer, such as table 2 in upper table:
The design of primers table of table 2
4th, using gene described in table 1 as template, corresponding nucleic acid fragment, Ran Houtong are expanded by PCR with the primer in table 2 Cross agarose gel electrophoresis and separate and recover specific purpose fragment;Each fragment is subjected to digestion and connection according to the combination in table 1; Connection product is reclaimed, bacillus coli DH 5 alpha is transferred to after connecting with corresponding carrier enzyme, obtains each expression plasmid.
5th, correct expression plasmid conversion e. coli bl21 (DE3) will be sequenced, the induced expression of albumen is carried out.Specifically Experimental implementation is referred to《Molecular cloning handbook》.
6th, the albumen of different molecular weight is isolated and purified
Carrier is purified for the albumen of pET21a plasmid expression with nickel ion affinity chromatograph;Carrier is pET28a-his-MBP Plasmid expression albumen maltose affinitive layer purification.The operating method and flow of specific various affinity column purifying can To be performed with reference to protein purification laboratory manual.
7th, can luminescent protein marker acquisition
The luminous intensity of each albumen, the i.e. binding ability to antibody are detected with Western Bolt respectively;According to single slice Luminous intensity, the egg of different molecular weight is mixed according to a certain percentage, mixed result is detected by Western Bolt, And mixed proportion is adjusted, finally give the homogeneous mixture of band.Detected by being incubated the different antibodies in different genera source The stability of luminous marker bands.
8th, the luminous marker of pre-dyed acquisition
The luminous marker mixed up and pre-dyed albumen marker (Solarbio, PR1910) is pressed 1:2 ratio mixing, is obtained To pre-dyed luminescent protein marker.
<110>Zhang Hailing
<120>Pre-dyed luminescent protein marker preparation method
<160> 9
<210> 1
<211> 159
<212> PRT
<213>Artificial sequence
<400> 1
MASMTGGQQM GRGSEFAQHD EAQQNAFYQV LNMPNLNADQ RNGFIQSLKD DPSQSANVLG 60
EAQKLNDSQA PKADAQQNNF NKDQQSAFYE ILNMPNLNEA QRNGFIQSLK DDPSQSTNVL 120
GEAKKLNESQ APKADNNFNK EQQNVDKLAA ALEHHHHHH 159
<210> 2
<211> 214
<212> PRT
<213>Artificial sequence
<400> 2
MASMTGGQQM GRGSEFAQHD EAQQNAFYQV LNMPNLNADQ RNGFIQSLKD DPSQSANVLG 60
EAQKLNDSQA PKADAQQNNF NKDQQSAFYE ILNMPNLNEA QRNGFIQSLK DDPSQSTNVL 120
GEAKKLNESQ APKADNNFNK EQQNAFYEIL NMPNLNEEQR NGFIQSLKDD PSQSANLLSE 180
AKKLNESQAP KADNKFNKNV DKLAAALEHH HHHH 214
<210> 3
<211> 326
<212> PRT
<213>Artificial sequence
<400> 3
MASMTGGQQM GRGSEFPELL GGPSVFIFPP KPKDTLMISR TPEVTCVVVD VSQDDPEVQF 60
TWYINNEQVR TARPPLREQQ FNSTIRVVST LPIAHQDWLR GKEFKCKVHN KALPAPIEKT 120
ISKARGQPLE PKVYTMGPPR EELSSRSVSL TCMINGFYPS DISVEWEKNG KAEDNYKTTP 180
AVLDSDGSYF LYSKLSVPTS EWQRGDVFTC SVMHEALHNH YTQKSISRSP GKVDPNLEGG 240
PSVFIFPPNI KDVLMISLTP KVTCVVVDVS EDDPDVRISW FVNNVEVHTA QTQTHREDYN 300
STIRVVSALP IQHQDAAALE HHHHHH 326
<210> 4
<211> 368
<212> PRT
<213>Artificial sequence
<400> 4
MASAQHDEAQ QNAFYQVLNM PNLNADQRNG FIQSLKDDPS QSANVLGEAQ KLNDSQAPKA 60
DAQQNNFNKD QQSAFYEILN MPNLNEAQRN GFIQSLKDDP SQSTNVLGEA KKLNESQAPK 120
ADNNFNKEQQ NAFYEILNMP NLNEEQRNGF IQSLKDDPSQ SANLLSEAKK LNESQAPKAD 180
NKFNKEQQNA FYEILHLPNL NEEQRNGFIQ SLKDDPSQSA NLLAEAKKLN DAQAPKADNK 240
FNKEQQNAFY EILHLPNLTE EQRNGFIQSL KDDPSVSKEI LAEAKKLNDA QEFGSSMTTY 300
KLILNGKTLK GETTTEAVDA ATAEKVFKQY ANDNGVDGEW TYDDATKTFT VTEVDKLAAA 360
LEHHHHHH 368
<210> 5
<211> 524
<212> PRT
<213>Artificial sequence
<400> 5
MASAQHDEAQ QNAFYQVLNM PNLNADQRNG FIQSLKDDPS QSANVLGEAQ KLNDSQAPKA 60
DAQQNNFNKD QQSAFYEILN MPNLNEAQRN GFIQSLKDDP SQSTNVLGEA KKLNESQAPK 120
ADNNFNKEQQ NAFYEILNMP NLNEEQRNGF IQSLKDDPSQ SANLLSEAKK LNESQAPKAD 180
NKFNKEQQNA FYEILHLPNL NEEQRNGFIQ SLKDDPSQSA NLLAEAKKLN DAQAPKADNK 240
FNKEQQNAFY EILHLPNLTE EQRNGFIQSL KDDPSVSKEI LAEAKKLNDA QEFPELLGGP 300
SVFIFPPKPK DTLMISRTPE VTCVVVDVSQ DDPEVQFTWY INNEQVRTAR PPLREQQFNS 360
TIRVVSTLPI AHQDWLRGKE FKCKVHNKAL PAPIEKTISK ARGQPLEPKV YTMGPPREEL 420
SSRSVSLTCM INGFYPSDIS VEWEKNGKAE DNYKTTPAVL DSDGSYFLYS KLSVPTSEWQ 480
RGDVFTCSVM HEALHNHYTQ KSISRSPGKV DKLAAALEHH HHHH 524
<210> 6
<211> 738
<212> PRT
<213>Artificial sequence
<400> 6
MASAQHDEAQ QNAFYQVLNM PNLNADQRNG FIQSLKDDPS QSANVLGEAQ KLNDSQAPKA 60
DAQQNNFNKD QQSAFYEILN MPNLNEAQRN GFIQSLKDDP SQSTNVLGEA KKLNESQAPK 120
ADNNFNKEQQ NAFYEILNMP NLNEEQRNGF IQSLKDDPSQ SANLLSEAKK LNESQAPKAD 180
NKFNKEQQNA FYEILHLPNL NEEQRNGFIQ SLKDDPSQSA NLLAEAKKLN DAQAPKADNK 240
FNKEQQNAFY EILHLPNLTE EQRNGFIQSL KDDPSVSKEI LAEAKKLNDA QEFPELLGGP 300
SVFIFPPKPK DTLMISRTPE VTCVVVDVSQ DDPEVQFTWY INNEQVRTAR PPLREQQFNS 360
TIRVVSTLPI AHQDWLRGKE FKCKVHNKAL PAPIEKTISK ARGQPLEPKV YTMGPPREEL 420
SSRSVSLTCM INGFYPSDIS VEWEKNGKAE DNYKTTPAVL DSDGSYFLYS KLSVPTSEWQ 480
RGDVFTCSVM HEALHNHYTQ KSISRSPGKV DPNLEGGPSV FIFPPNIKDV LMISLTPKVT 540
CVVVDVSEDD PDVRISWFVN NVEVHTAQTQ THREDYNSTI RVVSALPIQH QDWMSGKEFK 600
CKVNNKDLPS PIERTISKIK GLVRAPQVYI LPPPAEQLSR KDVSLTCLVV GFNPGDISVE 660
WTSNGHTEEN YKDTAPVLDS DGSYFIYSKL DIKTSKWEKT DSFSCNVRHE GLKNYYLKKT 720
ISRSPGKAAA LEHHHHHH 738
<210> 7
<211> 955
<212> PRT
<213>Artificial sequence
<400> 7
MGSSHHHHHH GSSMKIEEGK LVIWINGDKG YNGLAEVGKK FEKDTGIKVT VEHPDKLEEK 60
FPQVAATGDG PDIIFWAHDR FGGYAQSGLL AEITPDKAFQ DKLYPFTWDA VRYNGKLIAY 120
PIAVEALSLI YNKDLLPNPP KTWEEIPALD KELKAKGKSA LMFNLQEPYF TWPLIAADGG 180
YAFKYENGKY DIKDVGVDNA GAKAGLTFLV DLIKNKHMNA DTDYSIAEAA FNKGETAMTI 240
NGPWAWSNID TSKVNYGVTV LPTFKGQPSK PFVGVLSAGI NAASPNKELA KEFLENYLLT 300
DEGLEAVNKD KPLGAVALKS YEEELAKDPR IAATMENAQK GEIMPNIPQM SAFWYAVRTA 360
VINAASGRQT VDEALKDAQT NSSSNNNNNN NNNNLGIEEN LEVLFQGPVP GSPGSAQHDE 420
AQQNAFYQVL NMPNLNADQR NGFIQSLKDD PSQSANVLGE AQKLNDSQAP KADAQQNNFN 480
KDQQSAFYEI LNMPNLNEAQ RNGFIQSLKD DPSQSTNVLG EAKKLNESQA PKADNNFNKE 540
QQNAFYEILN MPNLNEEQRN GFIQSLKDDP SQSANLLSEA KKLNESQAPK ADNKFNKEQQ 600
NAFYEILHLP NLNEEQRNGF IQSLKDDPSQ SANLLAEAKK LNDAQAPKAD NKFNKEQQNA 660
FYEILHLPNL TEEQRNGFIQ SLKDDPSVSK EILAEAKKLN DAQEFPELLG GPSVFIFPPK 720
PKDTLMISRT PEVTCVVVDV SQDDPEVQFT WYINNEQVRT ARPPLREQQF NSTIRVVSTL 780
PIAHQDWLRG KEFKCKVHNK ALPAPIEKTI SKARGQPLEP KVYTMGPPRE ELSSRSVSLT 840
CMINGFYPSD ISVEWEKNGK AEDNYKTTPA VLDSDGSYFL YSKLSVPTSE WQRGDVFTCS 900
VMHEALHNHY TQKSISRSPG KVDTSVDLQL EIKRASQPEL APEDPEDVEH HHHHH 955
<210> 8
<211> 1684
<212> PRT
<213>Artificial sequence
<400> 8
MGSSHHHHHH GSSMKIEEGK LVIWINGDKG YNGLAEVGKK FEKDTGIKVT VEHPDKLEEK 60
FPQVAATGDG PDIIFWAHDR FGGYAQSGLL AEITPDKAFQ DKLYPFTWDA VRYNGKLIAY 120
PIAVEALSLI YNKDLLPNPP KTWEEIPALD KELKAKGKSA LMFNLQEPYF TWPLIAADGG 180
YAFKYENGKY DIKDVGVDNA GAKAGLTFLV DLIKNKHMNA DTDYSIAEAA FNKGETAMTI 240
NGPWAWSNID TSKVNYGVTV LPTFKGQPSK PFVGVLSAGI NAASPNKELA KEFLENYLLT 300
DEGLEAVNKD KPLGAVALKS YEEELAKDPR IAATMENAQK GEIMPNIPQM SAFWYAVRTA 360
VINAASGRQT VDEALKDAQT NSSSNNNNNN NNNNLGIEEN LEVLFQGPVP GSMKIEEGKL 420
VIWINGDKGY NGLAEVGKKF EKDTGIKVTV EHPDKLEEKF PQVAATGDGP DIIFWAHDRF 480
GGYAQSGLLA EITPDKAFQD KLYPFTWDAV RYNGKLIAYP IAVEALSLIY NKDLLPNPPK 540
TWEEIPALDK ELKAKGKSAL MFNLQEPYFT WPLIAADGGY AFKYENGKYD IKDVGVDNAG 600
AKAGLTFLVD LIKNKHMNAD TDYSIAEAAF NKGETAMTIN GPWAWSNIDT SKVNYGVTVL 660
PTFKGQPSKP FVGVLSAGIN AASPNKELAK EFLENYLLTD EGLEAVNKDK PLGAVALKSY 720
EEELAKDPRI AATMENAQKG EIMPNIPQMS AFWYAVRTAV INAASGRQTV DEALKDAQTE 780
FMKIEEGKLV IWINGDKGYN GLAEVGKKFE KDTGIKVTVE HPDKLEEKFP QVAATGDGPD 840
IIFWAHDRFG GYAQSGLLAE ITPDKAFQDK LYPFTWDAVR YNGKLIAYPI AVEALSLIYN 900
KDLLPNPPKT WEEIPALDKE LKAKGKSALM FNLQEPYFTW PLIAADGGYA FKYENGKYDI 960
KDVGVDNAGA KAGLTFLVDL IKNKHMNADT DYSIAEAAFN KGETAMTING PWAWSNIDTS 1020
KVNYGVTVLP TFKGQPSKPF VGVLSAGINA ASPNKELAKE FLENYLLTDE GLEAVNKDKP 1080
LGAVALKSYE EELAKDPRIA ATMENAQKGE IMPNIPQMSA FWYAVRTAVI NAASGRQTVD 1140
EALKDAQTVD AQHDEAQQNA FYQVLNMPNL NADQRNGFIQ SLKDDPSQSA NVLGEAQKLN 1200
DSQAPKADAQ QNNFNKDQQS AFYEILNMPN LNEAQRNGFI QSLKDDPSQS TNVLGEAKKL 1260
NESQAPKADN NFNKEQQNAF YEILNMPNLN EEQRNGFIQS LKDDPSQSAN LLSEAKKLNE 1320
SQAPKADNKF NKEQQNAFYE ILHLPNLNEE QRNGFIQSLK DDPSQSANLL AEAKKLNDAQ 1380
APKADNKFNK EQQNAFYEIL HLPNLTEEQR NGFIQSLKDD PSVSKEILAE AKKLNDAQEF 1440
PELLGGPSVF IFPPKPKDTL MISRTPEVTC VVVDVSQDDP EVQFTWYINN EQVRTARPPL 1500
REQQFNSTIR VVSTLPIAHQ DWLRGKEFKC KVHNKALPAP IEKTISKARG QPLEPKVYTM 1560
GPPREELSSR SVSLTCMING FYPSDISVEW EKNGKAEDNY KTTPAVLDSD GSYFLYSKLS 1620
VPTSEWQRGD VFTCSVMHEA LHNHYTQKSI SRSPGKLQLE IKRASQPELA PEDPEDVEHH 1680
HHHH 1684
<210> 9
<211> 1350
<212> PRT
<213>Artificial sequence
<400> 9
ATGGGTTCTT CTCACCATCA CCATCACCAT GGTTCTTCTA TGAAAATCGA AGAAGGTAAA 60
CTGGTAATCT GGATTAACGG CGATAAAGGC TATAACGGTC TCGCTGAAGT CGGTAAGAAA 120
TTCGAGAAAG ATACCGGAAT TAAAGTCACC GTTGAGCATC CGGATAAACT GGAAGAGAAA 180
TTCCCACAGG TTGCGGCAAC TGGCGATGGC CCTGACATTA TCTTCTGGGC ACACGACCGC 240
TTTGGTGGCT ACGCTCAATC TGGCCTGTTG GCTGAAATCA CCCCGGACAA AGCGTTCCAG 300
GACAAGCTGT ATCCGTTTAC CTGGGATGCC GTACGTTACA ACGGCAAGCT GATTGCTTAC 360
CCGATCGCTG TTGAAGCGTT ATCGCTGATT TATAACAAAG ATCTGCTGCC GAACCCGCCA 420
AAAACCTGGG AAGAGATCCC GGCGCTGGAT AAAGAACTGA AAGCGAAAGG TAAGAGCGCG 480
CTGATGTTCA ACCTGCAAGA ACCGTACTTC ACCTGGCCGC TGATTGCTGC TGACGGGGGT 540
TATGCGTTCA AGTATGAAAA CGGCAAGTAC GACATTAAAG ACGTGGGCGT GGATAACGCT 600
GGCGCGAAAG CGGGTCTGAC CTTCCTGGTT GACCTGATTA AAAACAAACA CATGAATGCA 660
GACACCGATT ACTCCATCGC AGAAGCTGCC TTTAATAAAG GCGAAACAGC GATGACCATC 720
AACGGCCCGT GGGCATGGTC CAACATCGAC ACCAGCAAAG TGAATTATGG TGTAACGGTA 780
CTGCCGACCT TCAAGGGTCA ACCATCCAAA CCGTTCGTTG GCGTGCTGAG CGCAGGTATT 840
AACGCCGCCA GTCCGAACAA AGAGCTGGCA AAAGAGTTCC TCGAAAACTA TCTGCTGACT 900
GATGAAGGTC TGGAAGCGGT TAATAAAGAC AAACCGCTGG GTGCCGTAGC GCTGAAGTCT 960
TACGAGGAAG AGTTGGCGAA AGATCCACGT ATTGCCGCCA CTATGGAAAA CGCCCAGAAA 1020
GGTGAAATCA TGCCGAACAT CCCGCAGATG TCCGCTTTCT GGTATGCCGT GCGTACTGCG 1080
GTGATCAACG CCGCCAGCGG TCGTCAGACT GTCGATGAAG CCCTGAAAGA CGCGCAGACT 1140
AATTCGAGCT CGAACAACAA CAACAATAAC AATAACAACA ACCTCGGGAT CGAGGAAAAC 1200
CTGGAAGTTC TGTTCCAGGG GCCGGTACCG GGATCCCCGG AATTCAAGCT TACTAGTGTC 1260
GACCTGCAGC TCGAGATCAA ACGGGCTAGC CAGCCAGAAC TCGCCCCGGA AGACCCCGAG 1320
GATGTCGAGC ACCACCACCA CCACCACTGA 1350

Claims (4)

1. a kind of pre-dyed luminescent protein marker preparation method, its step includes:
A, the CH genes for obtaining proteinA genes, proteinG genes, MBP genes, mouse and rabbit source antibody, are noted according to NCBI The IgG Binding domain for determining proteinA, proteinG are released, it is big according to each albumen in pre-dyed luminescent protein marker It is small that proteinA genes, proteinG genes, MBP genes, CH genes are cut or combined, albumen is retained in cutting process Binding domain;
B, proteinA, proteinG, MBP and CH gene after cutting or combination are connected on expression vector carried out respectively Expression and purification, the albumen purified;
C, the albumen of different molecular weight mixed according to a certain percentage, obtain luminescent protein marker;
D, the luminescent protein marker mixed up and pre-dyed albumen marker mixed in different ratio, by observing transferring film caudacoria Band brightness selection proper mixture ratio example on X films after upper stripe depth and development.
2. pre-dyed luminescent protein marker according to claim 1 preparation method, it is characterised in that:The expression vector For pET21a or pET28a.
3. pre-dyed luminescent protein marker according to claim 1 preparation method, it is characterised in that:The host cell For E.coli.
4. pre-dyed luminescent protein marker according to claim 1 preparation method, it is characterised in that:The luminescent protein Marker molecular weight is from 16kDa to 200kDa.
CN201710707539.4A 2017-08-17 2017-08-17 Pre-dyed luminescent protein marker preparation method Pending CN107298719A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201710707539.4A CN107298719A (en) 2017-08-17 2017-08-17 Pre-dyed luminescent protein marker preparation method

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201710707539.4A CN107298719A (en) 2017-08-17 2017-08-17 Pre-dyed luminescent protein marker preparation method

Publications (1)

Publication Number Publication Date
CN107298719A true CN107298719A (en) 2017-10-27

Family

ID=60131741

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201710707539.4A Pending CN107298719A (en) 2017-08-17 2017-08-17 Pre-dyed luminescent protein marker preparation method

Country Status (1)

Country Link
CN (1) CN107298719A (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110408639A (en) * 2019-08-01 2019-11-05 天德悦(北京)生物科技有限责任公司 Pre-dyed albumen marker and preparation method thereof, application can be exposed
CN111257557A (en) * 2020-01-23 2020-06-09 武汉爱博泰克生物科技有限公司 Immunoblotting one-step method
CN112724242A (en) * 2020-12-30 2021-04-30 西安德诺海思医疗科技有限公司 Method for producing recombinant human-like collagen and host cell protein by using pichia pastoris

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101556287A (en) * 2009-02-26 2009-10-14 杭州松华生物科技有限公司 Novel protein molecular weight standard and preparation method thereof
CN104862332A (en) * 2015-06-05 2015-08-26 武汉华美生物工程有限公司 Preparation method of protein exposure marker
US20160356784A1 (en) * 2014-05-01 2016-12-08 Kaohsiung Medical University Method for detecting protein by using secondary antibody detected epitope tag

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101556287A (en) * 2009-02-26 2009-10-14 杭州松华生物科技有限公司 Novel protein molecular weight standard and preparation method thereof
US20160356784A1 (en) * 2014-05-01 2016-12-08 Kaohsiung Medical University Method for detecting protein by using secondary antibody detected epitope tag
CN104862332A (en) * 2015-06-05 2015-08-26 武汉华美生物工程有限公司 Preparation method of protein exposure marker

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
YI MING ZHANG等: "Generate Western blot protein marker from a single construct", 《ANALYTICAL BIOCHEMISTRY》 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110408639A (en) * 2019-08-01 2019-11-05 天德悦(北京)生物科技有限责任公司 Pre-dyed albumen marker and preparation method thereof, application can be exposed
CN111257557A (en) * 2020-01-23 2020-06-09 武汉爱博泰克生物科技有限公司 Immunoblotting one-step method
CN111257557B (en) * 2020-01-23 2022-01-07 武汉爱博泰克生物科技有限公司 Immunoblotting one-step method
CN112724242A (en) * 2020-12-30 2021-04-30 西安德诺海思医疗科技有限公司 Method for producing recombinant human-like collagen and host cell protein by using pichia pastoris

Similar Documents

Publication Publication Date Title
CN107383208A (en) Luminescent protein marker preparation method
CN107298719A (en) Pre-dyed luminescent protein marker preparation method
CN101556287B (en) Novel protein molecular weight standard and preparation method thereof
Six et al. Two novel phycoerythrin-associated linker proteins in the marine cyanobacterium Synechococcus sp. strain WH8102
MXPA04001963A (en) Diagnosis of carcinomas.
WO2006034278A3 (en) Methods and compositions for detecting cancer using components of the u2 spliceosomal particle
CN108490177A (en) Nasopharyngeal carcinoma antibody test reagent, preparation method and nasopharyngeal carcinoma detection kit
WO2003042401A3 (en) Novel chromophores/fluorophores and methods for using the same
CN103728447A (en) Controllable quantum dot locus specificity bridging coupling antibody marking method and application
CN110003329A (en) Polypeptide, IL17A/F single domain antibody, nucleotide sequence and kit
CN106543272A (en) Multifunctional label fusion protein and its expression and application
CN114057870B (en) Labeled antibody for detecting novel coronavirus Delta mutant strain and application thereof
CN115073613A (en) Fusion protein GLuc-p30 and preparation method and application thereof
AU2003285844A1 (en) Fluorescent proteins and chromoproteins from non-aequorea hydrozoa species and methods for using same
DK1576157T3 (en) Fluorescent proteins from Copepode species and methods for using the same
RU2004125585A (en) NEW AEQUOREA COERULSCENS FLUORESCING PROTEINS AND WAYS OF THEIR APPLICATION
Thompson et al. Development of an epitope tag for the gentle purification of proteins by immunoaffinity chromatography: application to epitope-tagged green fluorescent protein
JP2009136280A (en) New peptide and its use
MX2022001068A (en) Humanized anti-il17a antibody and use thereof.
JP5712513B2 (en) Method for detecting human cytomegalovirus infection
Song et al. Engineered Single-Chain, Antiparallel, Coiled CoilMimics the MerR Metal BindingSite
CN111548412B (en) Hepatitis B surface antigen monoclonal antibody, preparation method, application and amino acid sequence
Sun et al. Identification and characterization of a novel calmodulin binding site in Drosophila TRP C-terminus
CN104862332A (en) Preparation method of protein exposure marker
TWI593967B (en) Secondary antibody detected epitope and use thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20171027

RJ01 Rejection of invention patent application after publication